title: Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer.
abstract: Lysosome-associated protein transmembrane 4ß-35 (LAPTM4B-35) is overexpressed in several solid malignancies. This study determines the expression level of LAPTM4B-35 in the cervical cancer during tumor development and progression. The present study investigated the clinicopathological significance of the coexpression of LAPTM4B-35 and VEGF in patients with cervical cancer. Immunohistochemistry was used to evaluate the expression of LAPTM4B-35 and VEGF in 62 cervical intraepithelial neoplasia (CIN) and 226 cervical carcinoma in comparison with 45 normal cervical specimens. The correlation of combined LAPTM4B-35 and VEGF with clinicopathologic characteristics was analyzed using a chi-squared test. Patient survival was determined using Kaplan-Meier method and log-rank test. A Cox regression analysis was performed to determine the prognostic significance of the factors. Combined LAPTM4B-35 and VEGF expression was significantly associated with FIGO stage (P = 0.014), tumor histologic grade (P = 0.033), lymph node metastasis (P = 0.045), and recurrence (P = 0.010). Kaplan-Meier survival analysis showed that patients with cervical cancer expressing both LAPTM4B-35 and VEGF exhibited both poor overall survival (OS) and disease-free survival (DFS) (P = 0.015 and P = 0.016, respectively). Cox analysis demonstrated that combined LAPTM4B-35 and VEGF expression was an independent factor for both OS and DFS (P = 0.015 and P = 0.016, respectively). Overexpression of LAPTM4B-35combined with positive VEGF expression may serve as a new biological marker to predict the prognosis of cervical carcinoma patients.
authors.affiliation: Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China.
authors.forename: Fanling
authors.initials: F
authors.lastname: Meng
authors.affiliation: Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China.
authors.forename: Shu
authors.initials: S
authors.lastname: Tan
authors.affiliation: Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China.
authors.forename: Tianbo
authors.initials: T
authors.lastname: Liu
authors.affiliation: Department of Pathology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China.
authors.forename: Hongtao
authors.initials: H
authors.lastname: Song
authors.affiliation: Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China. doctorlouge@126.com.
authors.forename: Ge
authors.initials: G
authors.lastname: Lou
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000235:genetics; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008565:Membrane Proteins / Q000096:biosynthesis* / Q000235:genetics; D008875:Middle Aged; D009367:Neoplasm Staging; D015513:Oncogene Proteins / Q000096:biosynthesis* / Q000235:genetics; D011237:Predictive Value of Tests; D011379:Prognosis; D002583:Uterine Cervical Neoplasms / Q000235:genetics* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; C477083:LAPTM4B protein, human; D008565:Membrane Proteins; D015513:Oncogene Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A
keywords: Cervical carcinoma; Immunohistochemistry; Lysosomal protein transmembrane 4 beta; Prognosis; Vascular endothelial growth factor